| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 29 Mar 2025 | 29 Mar 2025 |
| Outcome of Board meeting held on 29th March, 2025 for acceptance of the resignation tendered by Chief Financial Officer of the Company w.e.f. 31st March, 2025 | ||
| Board Meeting | 13 Feb 2025 | 5 Feb 2025 |
| MANGALAM DRUGS & ORGANICS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve Intimation of Board meeting to be held on 13th February 2025 for approval of Un-audited Financial results of the Company for the quarter ended 31st December 2024. Declaration of Un-Audited Financial Results for the quarter ended 31st December 2024 in the Board meeting held on 13th February 2025 (As Per BSE Announcement Dated on: 13/02/2025) | ||
| Board Meeting | 14 Nov 2024 | 8 Nov 2024 |
| MANGALAM DRUGS & ORGANICS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve Pursuant to Regulation 29 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Un-Audited Financial Results of the Company for the Quarter ended 30th September 2024. Board meeting held on 14th November 2024 for declaration of Un-Audited Satandalone and Consolidated Financial Results for the quareter ended 30th September, 2024 (As per BSE Announcement dated on 14/11/2024) | ||
| Board Meeting | 13 Aug 2024 | 6 Aug 2024 |
| MANGALAM DRUGS & ORGANICS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve Board Meeting to be held on 13th August 2024 intimation for approval of quarterly Financial Results of the Company for the quarter ended 30th June 2024 Approval of Un-audited Standalone and Consolidated Financial results for the quarter ended 30.06.2024 and re-appointment of Managing Director and Whole-time Director (As Per Bse Announcement Dated on 13.08.2024) | ||
| Board Meeting | 8 Jul 2024 | 9 Jul 2024 |
| Approval of appointment of Ms. Anuradha Pandey (ACS-72902) as a Company Secretary, Compliance Officer and Key Managerial Personnel of the Company w.e.f. 8th July, 2024 Board meeting dated 8th July , 2024 approved the appointment of Ms. Anuradha Pandey, (M.No. A72902) Company Secretary and Compliance Officer of the Company Board meeting held on 8th July, 2024 for approval of appointment of Ms. Anuradha Pandey (M. No. ACS-72902) Company Secretary and Compliance Officer and Key Managerial Personnel of the Company. (As Per BSE Announcement dated on 04.12.2024) | ||
| Board Meeting | 18 Jun 2024 | 18 Jun 2024 |
| Board meeting outcome for consideration and approval of Scheme of arrangement by absorption. | ||
| Board Meeting | 21 May 2024 | 14 May 2024 |
| Quarterly Results & Audited Results FINANCIAL RESULTS FOR THE PERIOD ENDED MARCH 31 2024 AND OTHER AGENDA ITEMS Appointment of Internal Auditor for the FY 2024 25 (As Per BSE Announcement Dated on 21.05.2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
